Cannabidiol (CBD), often in combination with clobazam, has emerged as a promising treatment for certain types of epilepsy, notably Lennox-Gastaut syndrome (LGS) and Dravet syndrome. However, for patients in the UK seeking access to these medicines on the National Health Service (NHS), getting a straightforward prescription is anything but simple. This blog unpicks how technology appraisal processes in the UK shape who can get cannabidiol with clobazam, when, and under what circumstances — highlighting the crucial distinction between legal prescribing and NHS funding. Along the way, we’ll also touch on important milestones such as the 2018 rescheduling, specialist-only restrictions, and NHS caution around unlicensed cannabis-based medicines.
Setting the Scene: What Is a Technology Appraisal in the UK?
First off, let’s clear what technology appraisals actually mean for patients. These appraisals are evaluations conducted by NICE (National Institute for Health and Care Excellence) or the Scottish Medicines Consortium (SMC) to assess if a new medicine or treatment offers value for money and clinical benefit sufficient to be funded by the NHS.
Put simply—if NICE or SMC gives a thumb’s-up through a positive technology appraisal, the NHS must make the treatment available to eligible patients, usually under a strict set of criteria.
One Sentence Patient Translation:
If NICE or SMC says it's okay, your doctor can prescribe it on the NHS, but only if you fit the exact rules they set.
The 2018 Rescheduling of Cannabis-Based Products: What Changed?
In November 2018, the UK government rescheduled cannabis-based products for medicinal use, moving them to Schedule 2 of the Misuse of Drugs Regulations. This shift finally made it legal for specialist doctors to prescribe cannabis-derived medicines legally across the UK.
- Before 2018: Prescribing cannabis-based products was effectively illegal with the exception of a few case-by-case licences. After 2018: Specialist doctors gained a clear legal framework to prescribe cannabis-based medicinal products (CBMPs).
This rescheduling was a landmark change because for the first time, patients with limited or no access previously could legally obtain these treatments by prescription. However, the rescheduling did not guarantee NHS funding — it merely paved the way for legal prescribing under specialist supervision.
What This Means For Patients
You can be prescribed cannabidiol and other cannabis-based medicines legally if a specialist thinks it’s right for you. But whether the NHS will pay for it is an entirely different question.
Understanding NHS Funding vs Legal Prescribing for Cannabidiol with Clobazam
Just because a specialist can legally prescribe cannabidiol with clobazam does not mean the NHS will automatically fund it. This is a key point often misunderstood by patients and clinics alike.
- Legal prescribing: Allowed under the 2018 rescheduling. A consultant in a specialist field can write a prescription for CBMPs, including cannabidiol formulations, if clinically appropriate. NHS funding: Determined by NHS England or NHS Scotland only after a rigorous assessment usually guided by technology appraisals from NICE or SMC.
Since 2019, NICE has assessed cannabidiol specifically in combination with clobazam as a treatment for certain types of treatment-resistant epilepsy. Their recommendation highlights that more info the NHS can fund cannabidiol-rich products for patients with Lennox-Gastaut syndrome or Dravet syndrome who are already on clobazam, but within very specific criteria. This represents the main NHS funded cannabis indication to date.
Things Marketing Says That Guidance Does NOT
- “You can get NHS-funded cannabidiol for any epilepsy.” – FALSE. It’s only for specific syndromes under strict conditions. “Your GP can prescribe cannabidiol with clobazam.” – FALSE. Only specialists can prescribe. “Cannabidiol is licensed for all seizure types.” – FALSE. Licensed indications are very narrow.
Specialist-Only Prescribing: Why This Rule Exists
One of the cornerstone regulations after the 2018 rescheduling is that only consultants with specialist qualifications relevant to the condition in question can prescribe cannabis-based medicines. GPs cannot do so under any normal circumstances.
This rule exists due to the complexity of managing epilepsy, the need to monitor drug interactions (especially clobazam and cannabidiol’s known pharmacokinetic interactions), and ongoing uncertainties about optimal dosing.
What this means practically is patients must be referred to epilepsy specialists within NHS clinics or private practices if they want to explore cannabidiol with clobazam treatment. This often causes delays or challenges in access because not all clinics are set up or willing to prescribe cannabis-based medicines.
Finding a Specialist Clinic
Sites like medicalcannabis.co.uk offer directories and comparison tools to help patients find clinics that are experienced in prescribing medical cannabis. However, patients should be aware that private clinics do not guarantee NHS funding and often charge consultation fees.
Unlicensed Cannabis-Based Medicines and NHS Caution
Most cannabis-based medicines remain unlicensed in the UK, including many cannabidiol formulations outside the specific NICE-approved products. The only licensed cannabis-derived medicine with NICE appraisal backing for epilepsy in the UK is Epidyolex (cannabidiol tablet), used alongside clobazam. Other cannabis-based medicines are used “off-label” or unlicensed and attract NHS caution.
NHS England is reluctant to routinely fund unlicensed products because safety, efficacy, and Website link pricing data can be patchy. They prefer licensed products supported by robust clinical data and technology appraisals.
This cautious approach reflects a broader ethos within the NHS: prioritizing treatments with proven benefits and established cost-effectiveness. Meanwhile, patients may access unlicensed cannabis products via private prescriptions or special access schemes, but these come at personal cost and uncertainty around quality assurance.
Prices: What Do We Know?
No specific prices were stated in the primary reviewed sources. If future data reveals exact pricing from manufacturers or the NHS, it should be quoted precisely with attribution. For now, it is understood that cannabidiol-based medicines, especially licensed ones like Epidyolex, are relatively expensive treatments, and cost considerations are factored into technology appraisals.
Summary Table: Key Points on UK Access to Cannabidiol with Clobazam
Aspect Details 2018 Rescheduling Legalised prescribing of cannabis-based medicines by specialists; enabled lawful prescriptions for CBD with clobazam. NHS Funding Requires positive technology appraisal (e.g. NICE appraisal for Epidyolex + clobazam); still rare and restricted to specific epilepsy syndromes. Legal Prescribing Allowed by specialist consultants only; GPs cannot prescribe CBD/cannabis products. Unlicensed CBMPs High NHS caution; mostly accessed privately; not routinely funded or recommended by NICE. Patient Clinics medicalcannabis.co.uk lists clinics prescribing CBMPs; exercise caution about NHS funding promises. Explainer Resources See releaf.co.uk for patient-friendly info on cannabis medicines and NHS access issues.Final Takeaway for Patients
If you or a loved one are exploring cannabidiol with clobazam as a treatment, understand these key points: It’s now legal for specialist doctors to prescribe it in the UK thanks to 2018 rescheduling, but NHS funding is limited to approved indications backed by technology appraisals, primarily for certain kinds of difficult epilepsy. Your GP can’t prescribe this medicine — you’ll need to see a specialist consultant. And while many cannabis-based products exist, only a few are licensed and supported by NICE guidance. Sites like medicalcannabis.co.uk can help find clinics that prescribe, but the NHS may not cover costs unless strict criteria are met.
Navigating this landscape can be tricky, but armed with knowledge about technology appraisals, legal prescribing rules, and NHS funding, patients can make informed decisions and realistic expectations.
